Annolyse
BriefingsCompaniesInsightsPrinciplesCompareWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology
  • Developers

© 2026 Annolyse. Analytical briefings for NZX company announcements.

Table of contents

  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material
←Back to briefings
Ryman Healthcare (RYM) / HY25

PBT up 21.9% but NPAT halved as tax swung from benefit to expense

Revenue and pre-tax growth look healthy, but the PBTF loss widened to -NZ$79.8m, equity fell 11.6%, and net debt pushed past NZ$2.57bn.

Release date
28 November 2024
Published
28 April 2026
Table of Contents⌄
  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material

What changed

Revenue rose 13.4% to NZ$366.3m, with Australia stepping up to 22.5% of group revenue from 16.3% (revenue NZ$82.3m vs NZ$52.5m) and New Zealand growing more modestly to NZ$283.1m. Profit before tax climbed 21.9% to NZ$174.8m, but reported NPAT fell 49.5% to NZ$94.4m as tax flipped from a NZ$43.3m benefit (HY24 effective rate ~30%) to an NZ$80.4m expense (effective rate ~46%). Operating cash flow declined 16.3% to NZ$282.8m, while capex was nearly halved to NZ$72.5m, leaving free cash flow before leases broadly flat at NZ$210.3m. Gross borrowings rose to NZ$2.6b (+3.7%), cash slipped to NZ$22.6m, and equity fell 11.6% to NZ$4.3b. No interim dividend was declared, consistent with HY24.

What matters

  • The non-GAAP measures point the other way. Ryman's preferred IFRS profit before tax and fair-value movements (PBTF) deteriorated to -NZ$79.8m from -NZ$17.8m, a much wider operating loss on Ryman's own definition. Reported PBT growth is therefore being held up by fair-value movements rather than underlying trading.
  • Capital base is shrinking while debt grows. Equity contracted by NZ$564.0m year on year while gross borrowings rose NZ$91.4m. Net debt of ~NZ$2.6b against a smaller equity base implies leverage has materially weakened, even before considering the wider PBTF loss.
  • Segment mix is shifting toward Australia at lower visible profitability. Australian revenue is up ~57%, but the segment result fell to NZ$34.9m from NZ$56.0m, and a small "Other" line carried a NZ$42.2m loss. The dominant New Zealand segment also saw segment result fall to NZ$101.6m from NZ$130.7m despite revenue growth.

Expectations

No formal targets, forward-work backlog, or quantitative guidance are disclosed in the extracted release. Annualised HY25 revenue of NZ$732.5m runs about 6.2% above the FY24 anchor of NZ$689.9m, so the topline run-rate is modestly ahead. However, FY24 NPAT collapsed to NZ$4.8m (HY24 NPAT NZ$186.7m, implying a ~NZ$182m second-half loss after FY24 fair-value charges of NZ$324.5m at the PBTF level), so HY-to-FY shape is dominated by year-end revaluations rather than a steady seasonal pattern. The release does not support a reliable extrapolation to full-year NPAT.

Quality of result

The headline PBT increase is the cleaner read on the period, but it benefits from fair-value movements that swing heavily at year-end and that Ryman itself strips out via PBTF — a measure that worsened by NZ$62.0m. Cash conversion deteriorated: operating cash flow fell NZ$55.1m on rising revenue, and the apparent FCF stability rests on capex being cut almost in half rather than on operating performance. Working capital also moved against the result, with extracted trade receivables of NZ$174.5m versus a near-zero comparator and operating working capital up NZ$168.1m, suggesting a meaningful timing/build component within the operating cash line. ROE roughly halved to 4.3% from 8.0%. Taken together, the durable component of the HY25 result looks smaller than the reported PBT and revenue growth imply.

Unresolved

  • The tax line swung by NZ$123.7m year on year with no explanation in the extract; a skeptical reader would want the deferred-tax versus current-tax split.
  • The reconciliation between reported PBT (+21.9%) and PBTF (-NZ$79.8m) is not in the extracted material, so the size and direction of underlying trading versus fair-value gains is not separable here.
  • Receivables of NZ$174.5m against a NZ$0.006m prior comparator looks like a presentation/reclassification rather than a true working-capital build, but the extract does not reconcile it; this materially affects how to read operating cash flow quality.
  • Capex was nearly halved without commentary on whether this reflects discipline, project completion, or deferral, which matters for the development pipeline and future revenue.
  • No interim dividend, no forward-work disclosure, and no FY25 guidance leave the trajectory toward FY25 NPAT and PBTF undefined.

This briefing cannot assess unit-level operating metrics such as occupancy, resales velocity, embedded value of occupation right agreements, or the development pipeline, none of which are present in the extracted data.

Key metrics

← Swipe to view more
Key metrics table for Ryman Healthcare HY25
Metric HY25 HY24 Change
Revenue $366.3m $323m +13.4% ↑
EBITDA — $146.3m —
Net profit after tax $94.4m $186.7m -49.5% ↓
Net cash inflow from operating activities $282.8m $337.9m -16.3% ↓
Declared dividend per share — 0.0c —
Profit before tax $174.8m $143.4m +21.9% ↑
Cash and cash equivalents $22.6m $33.3m -32.2% ↓
Total assets $12.8b $13.1b -2.1% ↓

Segment breakdown

← Swipe to view more
Segment breakdown table for Ryman Healthcare HY25
Segment Current revenue Prior revenue Current result Mix shift
New Zealand $283.1m $270.4m $101.6m -6.4pp
Australia $82.3m $52.5m $34.9m +6.2pp
Other $0.8m — −$42.2m n/a

Analytical metrics

← Swipe to view more
Analytical metrics table for Ryman Healthcare HY25
Metric HY25 HY24 Context
PBT growth +21.9% — cleaner earnings measure
Effective tax rate -46.0% 30.1% —
FCF pre-lease $210.3m $206.7m +$3.6m
FCF / NPAT 222.8% 110.7% complementary conversion metric
Capex % revenue 19.8% 40.6% —
Capex −$72.5m −$131.2m +$58.7m
Free cash flow — −$158.4m —
Debtor days 86.7 0.0 +86.7 days
Inventory days 0.9 4.7 -3.8 days
Operating working capital $176.4m $8.4m +$168.1m absorbed
Trade debtors $174.5m $0.01m +$174.5m
Net debt $2.6b $2.5b +$102.1m
Gross borrowings $2.6b $2.5b +$91.4m
ROE (annualised) 4.3% 8.0% Weakening
HY24 share of FY24 revenue 46.8% — Other half was 53.2%
HY24 share of FY24 NPAT n/m — Other half was n/m
Profit from continuing operations — $186.7m —

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Source-backed analysis from the filing set attached to this briefing.

Metric context

Trajectory before this result

A compact view of the company's recent revenue and margin path, derived from the same metrics history that powers the company page.

RYM revenue trajectory

Revenue context before the current result.

← Swipe to view more
RYM revenue trajectory preview table
PeriodRYM
HY26$413.8m
FY25$760.7m
HY25$366.3m
HY24$323m
HY23$274.2m

RYM EBITDA margin

Earnings margin across covered periods.

← Swipe to view more
RYM EBITDA margin preview table
PeriodRYM
HY269.7%
FY25n/a
HY25n/a
HY2445.3%
HY23n/a

Appendix

Reference material

Company materials considered in this briefing.

Current period

Ryman Healthcare Limited - Consolidated Interim Financial Statements - 30 September 2024

HY25 / financial report↗

Ryman Healthcare Limited - Media Release - 30 September 2024

HY25 / media release↗

Prior comparable period

Ryman Healthcare Limited - Announcement Numbers and Financial Statements - 30 September 2023

HY24 / financial report↗

Ryman Healthcare Limited - Media Release and Key Statistics - 30 September 2023

HY24 / media release↗

Full-year context

FY24 Result Press Release_FINAL

FY24 / results announcement↗

FY24 Result Press Release_FINAL

FY24 / results release↗

Ryman Healthcare Limited – Financial Statements – 31 March 2024 (including Deloitte Audit Report)

FY24 / financial report↗

Related insight

See how earnings quality compares across covered companies

→

Email updates

Want briefings like this for the next reporting season?

Get the next Annolyse briefing by email when it is published.

RYM revenue trajectory

Revenue context before the current result.

RYM EBITDA margin

Earnings margin across covered periods.